Harvey Schneier
Group for the Analysis of Development(PE)
Publications by Year
Research Areas
Gastrointestinal motility and disorders, Diabetes Treatment and Management, Intestinal Malrotation and Obstruction Disorders, Congenital gastrointestinal and neural anomalies, Gastroesophageal reflux and treatments
Most-Cited Works
- → Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety(2012)445 cited
- → A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation(2012)371 cited
- → Two Randomized Trials of Linaclotide for Chronic Constipation(2011)367 cited
- → Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)(2019)45 cited
- → Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes(2023)32 cited
- → Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight(2020)25 cited
- → Association of Baseline Characteristics With Insulin Sensitivity and β-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort(2020)20 cited
- → 286 Efficacy and Safety of Once Daily Linaclotide Administered Orally for 12-Weeks in Patients With Chronic Constipation: Results From 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials(2010)20 cited
- → Efficacy and Safety of Once Daily Linaclotide in Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial Followed by a 4-Week Randomized Withdrawal Period(2011)13 cited
- → Efficacy and Safety of Once-Daily Linaclotide Administered Orally for 26 Weeks in Patients With IBS-C: Results From a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial(2011)13 cited